Paper Details

  1. Home
  2. Paper Details

Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials.

Author: BlonskiJerzy Z, CalbeckaMalgorzata, CeglarekBernadetta, ChojnowskiKrzysztof, DmoszynskaAnna, Dwilewicz-TrojaczekJadwiga, Gora-TyborJoanna, HellmannAndrzej, KloczkoJanusz, KostyraAleksandra, KowalMalgorzata, KuliczkowskiKazimierz, LewandowskiKrzysztof, MitalAndrzej, NowakWieslaw, PotoczekStanislaw, RobakTadeusz, SeferynskaIlona, SkotnickiAleksander, Stella-HolowieckaBeata, SulekKazimierz, TrelinskiJacek, WarzochaKrzysztof, WiaterElzbieta, ZawilskaKrystyna

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Immune thrombocytopenia occurred in 7.1% of patients with chronic lymphocytic leukemia (CLL) treated with cladribine or chlorambucil. While the frequency of immune thrombocytopenia was similar between the two groups, the severity of bleeding was more pronounced in the cladribine group.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: The relationship between treatments of chronic lymphocytic leukemia (CLL) with cladribine (2-CdA) or chlorambucil and immune thrombocytopenia (IT) has not been yet determined. METHODS: The records of 777 patients in two randomized Polish Adult Leukemia Group (PALG)-CLL programs treated ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/ejh.12112

データ提供：米国国立医学図書館（NLM）

Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL), like a slow-moving sandstorm, can be a challenging condition to manage. This study, like a careful desert explorer studying the effects of different treatments, investigates the relationship between CLL treatments and immune thrombocytopenia (IT), a condition that affects platelet count.

The Impact of Treatments on Immune Thrombocytopenia

The researchers analyzed data from patients with CLL who received treatment with either cladribine or chlorambucil. They found that IT occurred in a significant percentage of patients, and there was no significant difference in IT prevalence between the two treatment groups. However, the time it took for IT to develop was significantly shorter in patients receiving cladribine-based regimens compared to those receiving chlorambucil.

Navigating the Treatment Landscape

This study provides valuable information for healthcare professionals treating patients with CLL. It highlights the need for careful monitoring of platelet counts and prompt treatment of IT when it occurs.

Dr.Camel's Conclusion

Just as a camel must carefully navigate a desert landscape, healthcare providers must carefully manage the treatment of CLL and its potential complications. This study provides valuable insights into the link between CLL treatments and immune thrombocytopenia, helping us better understand this condition and develop effective treatment strategies.

Date :
  1. Date Completed 2013-12-23
  2. Date Revised 2013-06-20
Further Info :

Pubmed ID

23521128

DOI: Digital Object Identifier

10.1111/ejh.12112

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.